Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pramipexole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.97 |
| ▸ | HRH2 | P25021 | 2/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.97 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | HTR1B | P28222 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | HTR7 | P34969 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.97 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.97 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.55 |
| ▸ | SCN4A | P35499 | 4/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramipexole SCHEMBL3102892 | 1.00 | DRD3 (0.97) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL20524815 | 1.00 | DRD3 (0.97) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL28361114 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL22165339 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL28506481 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL2048695 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL743891 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Dexpramipexole SCHEMBL2289178 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL153875 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL28345162 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776131-B1 | COMPOSITION FOR TREATING OR PREVENTING NEURODEGENERATIVE DISORDERS | BIOLOGISCHE HEILMITTEL HEEL GMBH (DE) | 2024-05-15 | — | — | EP | claimed |
| CN-113292440-A | Preparation method of N, N-diisopropylethylenediamine and preparation method of pramiperacetam monohydrate | 浙江朗华制药有限公司 | 2021-08-24 | — | — | CN | claimed |
| CN-113185442-A | Pramipexole hydrate crystal and preparation method thereof | 许昌远志生物科技有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-111875530-A | Pramipexole hydrate crystal and preparation method thereof | 浙江朗华制药有限公司 | 2020-11-03 | — | — | CN | claimed |
| EP-2870961-B1 | Effervescent formulations of pramipexole | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2018-07-18 | — | — | EP | claimed |
| EP-2568999-B1 | ACTH FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | MALLINCKRODT ARD IP LTD (IE) | 2018-07-11 | — | — | EP | claimed |
| EP-2364694-B1 | Controlled-release formulations of pramipexole | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2013-11-06 | — | — | EP | claimed |
| EP-1536792-B1 | PRAMIPEXOLE ONCE-DAILY DOSAGE FORM | PHARMACIA LLC (US) | 2013-09-18 | — | — | EP | claimed |
| EP-2295040-B1 | Pharmaceutical compositions of pramipexole | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2011-10-12 | — | — | EP | claimed |
| EP-1781260-B9 | EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2011-02-16 | — | — | EP | claimed |
| EP-1781260-B1 | EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2010-11-03 | — | — | EP | claimed |
| EP-1531814-B1 | SUSTAINED-RELEASE TABLET COMPOSITION OF PRAMIPEXOLE | PHARMACIA CORP (US) | 2008-08-27 | — | — | EP | claimed |
| US-20240238295-A1 | METHOD FOR MODULATING NEUROPATHIES | CHENGDU WENDING TECHNOLOGY DEVELOPMENT CO., LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| CN-118056566-A | Method and pharmaceutical composition for regulating neuropathy | 成都文鼎科技发展有限公司 | 2024-05-21 | — | — | CN | disclosed |
| EP-4342471-A1 | METHOD FOR MODULATING NEUROPATHIES | Chengdu Wending Technology Development Co., Ltd. (CN) | 2024-03-27 | — | — | EP | disclosed |
| CN-117752663-A | A method for regulating neuropathy | 成都文鼎科技发展有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-2086536-A1 | THE USE OF PRAMIPEXOLE OR A SALT THEREOF FOR THE TREATMENT OF PARKINSON'S DISEASE | Boehringer Ingelheim International GmbH (DE) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008104847-A3 | PROCESSES FOR THE PREPARATION OF PRAMIPEXOLE AND SALTS THEREOF | WOCKHARDT RESEARCH CENTER (IN) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008104847-A2 | PROCESSES FOR THE PREPARATION OF PRAMIPEXOLE AND SALTS THEREOF | WOCKHARDT RESEARCH CENTRE (IN) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008052953-A1 | THE USE OF PRAMIPEXOLE OR A SALT THEREOF FOR THE TREATMENT OF PARKINSON'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238295-A1 | METHOD FOR MODULATING NEUROPATHIES | MME, PMP22, NEFM | DRD3 1092/4885DRD2 773/4885DRD4 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.